IDEXX Laboratories, Inc. vs TJX Companies Inc — how do they compare? IDEXX Laboratories, Inc. trades at $557.02 (market cap $44.48B), while TJX Companies Inc trades at $153.22 (market cap $172.00B). The key difference: TJX Companies Inc is far larger — about 3.9× IDEXX Laboratories, Inc.'s market cap, and TJX Companies Inc pays a 1.23% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | TJX | |
|---|---|---|
Market Cap | $44.48B | $172.00B |
Sector | Health | Consumer Cyclical |
52-Week High | $766.68 | $168.41 |
52-Week Low | $520.87 | $124.53 |
Enterprise Value | $45.38B | $180.60B |
Dividend Yield | — | 1.23% |
Signals from Pluang's Aura AI — not financial advice
IDXX trades at $563.79, down 0.64% today but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $563 and resistance at $572, while valuation metrics remain elevated. Recent Q1 2026 results exceeded expectations with EPS of $3.47 versus $3.41 estimates, supporting the company's leadership in veterinary diagnostics.
Outlook remains positive given strong analyst support (59% buy ratings) and innovation pipeline, though premium valuations and competitive pressures present risks. Revenue growth trajectory and expanding margins provide fundamental support for continued upside potential in the pet healthcare sector.
TJX trades at $155.47, up 0.7% on the day, with a bullish technical signal and strong fundamental performance. The company has consistently beaten earnings expectations, with Q1 2026 EPS of $1.19 surpassing the $1.02 estimate. Revenue growth is robust, reaching $56.36 billion in 2025, with a net income margin of 9.4%. Analyst sentiment is overwhelmingly positive, with 88% recommending Buy and a consensus price target of $181.80, suggesting significant upside potential from current levels.
The outlook for TJX remains favorable, driven by sustained earnings beats, expanding margins, and strategic international growth. Key risks include competitive pressures in discount retail and sensitivity to consumer spending trends. With strong cash flow generation supporting dividends and buybacks, TJX presents a compelling growth story, though valuation metrics like a P/E of 30.05 warrant monitoring for overextension.
Trailing returns across standard periods
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.
Read more on TJX →